Similarly, primary EGFR‐mutated lung cancer cells (MGH119) showed higher CEACAM5 and epithelial marker CLDN1 expression but lower mesenchymal marker CDH2 expression than their EGFR‐TKI gefitinib‐resistant counterparts (MGH119GR) (Figure 4B). This evidence concerns the gene CDH2 and lung carcinoma.